Skip to Main Content

Paper Details

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Clin Gastroenterol Hepatol
21
2023
Author NameAffiliation
William J SandbornUniversity of California San Diego
  • 1 - 1

Datasets

Release 1.2